Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH)
Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025
Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024
Webcast to be held today, August 8, 2024, at 8:30 am ET
| Conference Call Information: | ||
| Date: | Thursday, August 8, 2024 | |
| Time: | 8:30 am Eastern Time | |
| Webcast: | To listen, the conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors. | |
| Dial-in: | To participate or dial-in, register here to receive the dial-in numbers and unique PIN to access the call. | |
Following the conclusion of the call, the webcast will be available for replay on the Investor Relations (IR) page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.